Claims for Patent: 10,799,505
✉ Email this page to a colleague
Summary for Patent: 10,799,505
| Title: | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| Abstract: | A novel crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrim- idin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrim- idin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form. |
| Inventor(s): | Arrigo; Alisha B. (Boulder, CO), Juengst; Derrick (Boulder, CO), Shah; Khalid (South San Francisco, CA) |
| Assignee: | Array BioPharma, Inc. (Boulder, CO) |
| Application Number: | 14/943,014 |
| Patent Claims: |
1. A crystalline form (I-HS) having the formula: ##STR00007## wherein the crystalline form is substantially free of the amorphous form.
2. The crystalline form according to claim 1, characterized by having XRPD diffraction peaks (2.theta. degrees) at 18.4.+-.0.2, 20.7.+-.0.2, 23.1.+-.0.2, and 24.0.+-.0.2. 3. The crystalline form according to claim 1, characterized by having XRPD diffraction peaks (2.theta. degrees) at 10.7.+-.0.2, 18.4.+-.0.2, 20.7.+-.0.2, 23.1.+-.0.2, and 24.0.+-.0.2. 4. The crystalline form according to claim 1, characterized by having XRPD diffraction peaks (2.theta. degrees) at 10.7.+-.0.2, 18.4.+-.0.2, 19.2.+-.0.2, 20.2.+-.0.2, 20.7.+-.0.2, 21.5.+-.0.2, 23.1.+-.0.2, and 24.0.+-.0.2. 5. The crystalline form according to claim 1, characterized by having XRPD diffraction peaks (2.theta. degrees) at 10.7.+-.0.2, 15.3.+-.0.2, 16.5.+-.0.2, 18.4.+-.0.2, 19.2.+-.0.2, 19.9.+-.0.2, 20.2.+-.0.2, 20.7.+-.0.2, 21.5.+-.0.2, 22.1.+-.0.2, 23.1.+-.0.2, 24.0.+-.0.2, 24.4.+-.0.2, 25.6.+-.0.2, 26.5.+-.0.2, 27.6.+-.0.2, 28.2.+-.0.2, 28.7.+-.0.2, 30.8.+-.0.2, and 38.5.+-.0.2. 6. The crystalline form according to claim 1, wherein the crystalline form has XRPD pattern substantially as shown in FIG. 29. 7. The crystalline form according to claim 1, wherein the crystalline form exhibits an onset to maximum of about 193 to about 205.degree. Celsius, as measured by differential scanning calorimetry. 8. The crystalline form according to claim 1, wherein the crystalline form exhibits a heat of melting of about 2.415 mW, as measured by differential scanning calorimetry. 9. The crystalline form according to claim 1, wherein the crystalline form has a DSC thermogram substantially as shown in FIG. 26. 10. The crystalline form according to claim 1, wherein the crystalline form is non-hygroscopic. 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a crystalline form according to claim 1. 12. A pharmaceutical composition made by mixing a crystalline form according to claim 1 and a pharmaceutically acceptable carrier. 13. The crystalline form (I-HS) according to claim 1, prepared by a process comprising: (a) mixing (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate having an ethanol impurity with a 5:95 w/w solution of water/2-butanone; (b) heating the mixture from step (d) at about 65-70.degree. C. with stirring until the weight percent of ethanol is about 0.5% to form a slurry of the crystalline form of (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate; and (c) isolating the crystalline form of (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate, substantially free of the amorphous form, by filtration. 14. The crystalline form (I-HS) according to claim 13, wherein the (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate having an ethanol impurity is prepared by (a) adding concentrated sulfuric acid to a solution of (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide in ethanol to form the hydrogen sulfate salt of (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (b) adding heptane to the solution in Step (a) to form a slurry; and (c) filtering the slurry to isolate (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,- 5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. 15. The crystalline form according to claim 14, made by a process further comprising: (b1) seeding the solution from step (a) with (S)--N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate at room temperature and allowing the solution to stir until a slurry forms. |
